{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:52:44Z","timestamp":1780919564218,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3J1341, CMRPG3M1691"],"award-info":[{"award-number":["CMRPG3J1341, CMRPG3M1691"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06765-z","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:25:10Z","timestamp":1751383510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Baseline serum EV-miR-1-3p as a protective factor and biomarker for hepatocellular carcinoma development after HCV eradication"],"prefix":"10.1186","volume":"23","author":[{"given":"Wei","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiChieh Julie","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Chang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"3","key":"6765_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"6765_CR2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1111\/j.1440-1746.2011.06785.x","volume":"26","author":"SR Walter","year":"2011","unstructured":"Walter SR, Thein HH, Gidding HF, Amin J, Law MG, George J, et al. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. J Gastroenterol Hepatol. 2011;26(12):1757\u201364.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5 Pt 1","key":"6765_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329\u201337.","journal-title":"Ann Intern Med"},{"issue":"5","key":"6765_CR4","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ijc.30521","volume":"140","author":"S Manthravadi","year":"2017","unstructured":"Manthravadi S, Paleti S, Pandya P. Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. Int J Cancer. 2017;140(5):1042\u20139.","journal-title":"Int J Cancer"},{"issue":"11","key":"6765_CR5","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1245\/s10434-017-6008-y","volume":"24","author":"H Shinkawa","year":"2017","unstructured":"Shinkawa H, Hasegawa K, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, et al. Impact of sustained virological response to interferon therapy on recurrence of hepatitis C Virus-Related hepatocellular carcinoma. Ann Surg Oncol. 2017;24(11):3196\u2013202.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"6765_CR6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/jvh.12745","volume":"24","author":"W Teng","year":"2017","unstructured":"Teng W, Hsieh YC, Lui KW, Chen WT, Hung CF, Huang CH, et al. Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization. J Viral Hepat. 2017;24(12):1160\u20137.","journal-title":"J Viral Hepat"},{"issue":"6","key":"6765_CR7","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204\u201312.","journal-title":"J Hepatol"},{"issue":"3","key":"6765_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jvh.13232","volume":"27","author":"SA McDonald","year":"2020","unstructured":"McDonald SA, Pollock KG, Barclay ST, Goldberg DJ, Bathgate A, Bramley P, et al. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. J Viral Hepat. 2020;27(3):270\u201380.","journal-title":"J Viral Hepat"},{"issue":"4","key":"6765_CR9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","volume":"156","author":"D Thabut","year":"2019","unstructured":"Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology. 2019;156(4):997\u20131009. e5.","journal-title":"Gastroenterology"},{"key":"6765_CR10","doi-asserted-by":"publisher","first-page":"27066","DOI":"10.3402\/jev.v4.27066","volume":"4","author":"M Yanez-Mo","year":"2015","unstructured":"Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.","journal-title":"J Extracell Vesicles"},{"issue":"7","key":"6765_CR11","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.7150\/thno.30958","volume":"9","author":"X-P Tian","year":"2019","unstructured":"Tian X-P, Wang C-Y, Jin X-H, Li M, Wang F-W, Huang W-J, et al. Acidic microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage hepatocellular carcinoma to promote Cancer cell proliferation and metastasis. Theranostics. 2019;9(7):1965\u201379.","journal-title":"Theranostics"},{"issue":"1","key":"6765_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"12","key":"6765_CR13","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/jvh.12578","volume":"23","author":"V Knop","year":"2016","unstructured":"Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat. 2016;23(12):994\u20131002.","journal-title":"J Viral Hepat"},{"issue":"6","key":"6765_CR14","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","volume":"64","author":"GR Foster","year":"2016","unstructured":"Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64(6):1224\u201331.","journal-title":"J Hepatol"},{"issue":"10","key":"6765_CR15","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1111\/jgh.15538","volume":"36","author":"WF Hsu","year":"2021","unstructured":"Hsu WF, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, et al. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). J Gastroenterol Hepatol. 2021;36(10):2884\u201392.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"6765_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727\u201333.","journal-title":"J Hepatol"},{"issue":"1","key":"6765_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/apt.14380","volume":"47","author":"E Ogawa","year":"2018","unstructured":"Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther. 2018;47(1):104\u201313.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"6765_CR18","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/liv.13700","volume":"38","author":"L Santangelo","year":"2018","unstructured":"Santangelo L, Bordoni V, Montaldo C, Cimini E, Zingoni A, Battistelli C, et al. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles MicroRNAs content and on their Immunomodulating properties. Liver Int. 2018;38(10):1741\u201350.","journal-title":"Liver Int"},{"key":"6765_CR19","doi-asserted-by":"crossref","unstructured":"Zeng Y, Hu S, Luo Y, He K. Exosome cargos as biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Pharmaceutics. 2023;15(9).","DOI":"10.3390\/pharmaceutics15092365"},{"key":"6765_CR20","doi-asserted-by":"publisher","first-page":"700649","DOI":"10.3389\/fonc.2021.700649","volume":"11","author":"Z Lyu","year":"2021","unstructured":"Lyu Z, Yang M, Yang T, Ma M, Yang Z. Metal-Regulatory transcription Factor-1 targeted by miR-148a-3p is implicated in human hepatocellular carcinoma progression. Front Oncol. 2021;11:700649.","journal-title":"Front Oncol"},{"issue":"7","key":"6765_CR21","doi-asserted-by":"publisher","first-page":"e2916","DOI":"10.1038\/cddis.2017.309","volume":"8","author":"L Cheng","year":"2017","unstructured":"Cheng L, Zhu Y, Han H, Zhang Q, Cui K, Shen H, et al. MicroRNA-148a deficiency promotes hepatic lipid metabolism and hepatocarcinogenesis in mice. Cell Death Dis. 2017;8(7):e2916.","journal-title":"Cell Death Dis"},{"issue":"2","key":"6765_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/jcmm.14045","volume":"23","author":"Y Deng","year":"2019","unstructured":"Deng Y, Wang J, Huang M, Xu G, Wei W, Qin H. Inhibition of miR-148a-3p resists hepatocellular carcinoma progress of hepatitis C virus infection through suppressing c-Jun and MAPK pathway. J Cell Mol Med. 2019;23(2):1415\u201326.","journal-title":"J Cell Mol Med"},{"key":"6765_CR23","doi-asserted-by":"publisher","first-page":"865472","DOI":"10.3389\/fgene.2022.865472","volume":"13","author":"TM Carvalho","year":"2022","unstructured":"Carvalho TM, Brasil GO, Jucoski TS, Adamoski D, de Lima RS, Spautz CC, et al. MicroRNAs miR-142-5p, miR-150-5p, miR-320a-3p, and miR-4433b-5p in serum and tissue: potential biomarkers in sporadic breast Cancer. Front Genet. 2022;13:865472.","journal-title":"Front Genet"},{"key":"6765_CR24","doi-asserted-by":"crossref","unstructured":"Ozawa PMM, Vieira E, Lemos DS, Souza ILM, Zanata SM, Pankievicz VC et al. Identification of MiRNAs enriched in extracellular vesicles derived from serum samples of breast Cancer patients. Biomolecules. 2020;10(1).","DOI":"10.3390\/biom10010150"},{"key":"6765_CR25","doi-asserted-by":"crossref","unstructured":"Tadros SA, Attia YM, Maurice NW, Fahim SA, Abdelwahed FM, Ibrahim S et al. Thymoquinone suppresses angiogenesis in DEN-Induced hepatocellular carcinoma by targeting miR-1-3p. Int J Mol Sci. 2022;23(24).","DOI":"10.3390\/ijms232415904"},{"key":"6765_CR26","doi-asserted-by":"publisher","first-page":"652292","DOI":"10.3389\/fcell.2021.652292","volume":"9","author":"H Chen","year":"2021","unstructured":"Chen H, Bao L, Hu J, Wu D, Tong X. ORC6, negatively regulated by miR-1-3p, promotes proliferation, migration, and invasion of hepatocellular carcinoma cells. Front Cell Dev Biol. 2021;9:652292.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"6765_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10020-020-00259-y","volume":"27","author":"P Deng","year":"2021","unstructured":"Deng P, Li K, Gu F, Zhang T, Zhao W, Sun M, et al. LINC00242\/miR-1-3p\/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis. Mol Med. 2021;27(1):9.","journal-title":"Mol Med"},{"issue":"6","key":"6765_CR28","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1159\/000343336","volume":"30","author":"G Li","year":"2012","unstructured":"Li G, Cai M, Fu D, Chen K, Sun M, Cai Z, et al. Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma. Cell Physiol Biochem. 2012;30(6):1481\u201390.","journal-title":"Cell Physiol Biochem"},{"key":"6765_CR29","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.2147\/IJN.S506542","volume":"20","author":"Q Jiang","year":"2025","unstructured":"Jiang Q, Ning F, Jia Q, Wang H, Xue W, Wang J, et al. MiR-148a-3p loaded human umbilical cord mesenchymal stem Cell-Derived extracellular vesicles alleviates Silica-Induced pulmonary fibrosis by inhibiting beta-Catenin signaling. Int J Nanomed. 2025;20:4319\u201336.","journal-title":"Int J Nanomed"},{"issue":"1","key":"6765_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10620-022-07621-6","volume":"68","author":"YC Liu","year":"2023","unstructured":"Liu YC, Cheng YT, Chen YC, Hsieh YC, Jeng WJ, Lin CY, et al. Comparing predictability of Non-invasive tools for hepatocellular carcinoma in treated chronic hepatitis C patients. Dig Dis Sci. 2023;68(1):323\u201332.","journal-title":"Dig Dis Sci"},{"key":"6765_CR31","doi-asserted-by":"crossref","unstructured":"Kao YT, Liu YC, Cheng YT, Wen YW, Hsieh YC, Hsu CE et al. Hepatocellular carcinoma incidences and risk factors in hepatitis C patients: interferon versus Direct-Acting agents. Viruses. 2024;16(9).","DOI":"10.3390\/v16091485"},{"issue":"7","key":"6765_CR32","first-page":"3164","volume":"12","author":"HW Wang","year":"2022","unstructured":"Wang HW, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, et al. Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study. Am J Cancer Res. 2022;12(7):3164\u201374.","journal-title":"Am J Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06765-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06765-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06765-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:25:12Z","timestamp":1751383512000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06765-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6765"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06765-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The investigational protocol was approved by the ethics committee of Chang Gung Memorial Hospital, Linkou Medical Center (202002382B0). Informed consent was obtained from all study participants. All the experiments were performed in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"722"}}